Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
.
. .
.
Chrome 2001
Chrome 2001
Health News Health News
.
Psychotherapy May Be Effective Alternate Treatment for Schizophrenia, Study Finds
February 06, 2014

 

THURSDAY, Feb. 6, 2014 (HealthDay News) -- A form of psychotherapy known as cognitive behavioral therapy may be an effective option for schizophrenia patients who are unable or unwilling to take antipsychotic drugs, a new study suggests.

Reporting Feb. 6 in The Lancet, British researchers say that the treatment can help ease patients' psychotic symptoms and boost their personal and social functioning.

They note that many people with schizophrenia cannot take standard medications.

"As many as half of all people with schizophrenia choose not to take drugs because of side effects that can include serious weight gain, development of metabolic disorders and an increased risk of sudden cardiac death, because the treatment is not felt to be effective, or because they do not perceive that they need treatment," study author Anthony Morrison, from the University of Manchester, said in a journal news release.

"Currently, no evidence-based safe and effective treatment alternative exists," he added.

To see if cognitive behavioral therapy might work in these cases, Morrison's team tracked the outcomes of 74 schizophrenia patients aged 16-65 who had stopped taking antipsychotic drugs for at least six months.

As part of the treatment, a therapist worked with some of the patients to help them change detrimental thought patterns and behaviors.

The patients in the cognitive behavioral therapy group showed greater improvements after 18 months than those who didn't receive the therapy, the study found.

Prior research has shown that schizophrenia patients benefits from cognitive therapy in combination with antipsychotic drugs, but the effectiveness of cognitive therapy in patients who were not taking medication hadn't been known.

The findings show "that cognitive therapy is an acceptable intervention for a population who are usually considered to be very challenging to engage in mental health services," Morrison said.

Two experts in the United States said these early results are promising, but more study may be needed.

"Non-compliance or medication refusal is a substantial therapeutic issue" when treating patients with schizophrenia, said Dr. Russell Joffe, chairman of psychiatry and behavioral science at Staten Island University Hospital, in New York City.

He noted that's there's been good data to support the use of cognitive behavioral therapy in mood or anxiety disorders, "but there is limited data in psychotic disorders" such as schizophrenia. Still, the study was small and focused on short-term treatment, whereas "schizophrenia is a chronic and persistent mental illness," Joffe said.

"Demonstrating the effectiveness of new treatments for major psychiatric illness is always a good thing, given the enormous burden of suffering," he said. "This data, however, is very preliminary and further research needs to be done before confronting the substantial logistic challenges in implementing such treatment on a broad clinical basis."

Dr. Mary Badaracco is a professor at the NYU School of Medicine and the director of psychiatry at Bellevue Hospital Center in New York City. She said the study "adds to the growing body of evidence supporting the usefulness of cognitive behavioral therapy approaches in patients with schizophrenia, an illness that can cause lifelong suffering and heartbreaking disability."

She stressed, however, that "the results of this study should not be used to encourage patients not to take medications, which remain the mainstay of treatment."

Morrison's team agreed with Badaracco that schizophrenia patients on antipsychotics should not suddenly stop taking the drugs. They should first discuss the matter with their doctor.

"The study does, however, underline the usefulness of cognitive behavioral therapy -- an intervention that is free of the sometimes intolerable effects of some medications," Badaracco said. The new finding may also provide "another source of hope for the 1 percent of the world's population that suffers from this illness."

More information

The U.S. National Institute of Mental Health has more about schizophrenia.


SOURCES: Russell Joffe, M.D, chairman, psychiatry and behavioral science, Staten Island University Hospital, New York City; Mary Badaracco, M.D, professor, NYU School of Medicine, and director, psychiatry, Bellevue Hospital Center, New York City; The L...

InteliHealth
.
.
.
.
.
More News
InteliHealth .
.
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
HIV/AIDS News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Schizophrenia
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
.
.
.
.
InteliHealth
    Print Printer-friendly format    
   
.  
This website is certified by Health On the Net Foundation. Click to verify.
.